查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1510454

gRNA 市場 - 全球產業規模、佔有率、趨勢、機會和預測，按類型、產品和服務（產品、客製化 gRNA 合成服務）、應用、最終用途、地區和競爭細分，2019-2029 年

gRNA Market- Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type, By Product & Services (Product, Custom gRNA Synthesis Services), By Application, By End-Use, By Region and Competition, 2019-2029F
出版日期: | 出版商: TechSci Research | 英文 182 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

2023 年全球 gRNA 市場價值為 4.9823 億美元，預計到 2029 年將以 18.54% 的複合年成長率成長。隨著生物技術和分子生物學的進步不斷加速，對精確、高效的基因組編輯工具的需求顯著上升，推動了gRNA市場的擴張。 gRNA 是 CRISPR（成簇規則間隔短回文重複序列）技術的關鍵組成部分，可實現基因的標靶修飾。這項革命性技術可應用於各個領域，包括農業、醫療保健和研究。在農業中，在基於 CRISPR 的基因組編輯中使用 gRNA 有可能透過增強產量、抗病性和營養成分等性狀來徹底改變作物改良。醫療保健產業也見證了 gRNA 技術用於治療目的的激增，包括開發針對遺傳性疾病和癌症的新型療法。 gRNA 的多功能性使科學家和研究人員能夠精確定位和修改特定基因，為個人化醫療開闢了可能性。 gRNA 市場的特點是持續不斷的研究和開發活動，旨在完善和擴展 CRISPR 技術的能力。開發更有效率、更精確的基因組編輯工具的競賽促進了生技公司、學術機構和研究組織之間的合作。因此，gRNA 市場預計在未來幾年將持續成長。然而，與基因組編輯技術相關的倫理和監管挑戰，包括對脫靶效應和意外後果的擔憂，對市場的擴張構成了潛在的障礙。在技​​術進步和倫理考量之間取得平衡對於 gRNA 市場的持續成長至關重要。儘管面臨挑戰，gRNA 技術的潛在應用和變革性影響使其成為快速發展的基因工程領域的焦點。

市場概況
預測期 2025-2029
2023 年市場規模 4.9823億美元
2029 年市場規模 137040萬美元
2024-2029 年複合年成長率 18. 54%
成長最快的細分市場 製藥與生物技術公司
最大的市場 北美洲

主要市場促進因素

基因工程的進展

增加研發活動

對個人化醫療的需求不斷成長

主要市場挑戰

脫靶效應

配送方式

主要市場趨勢

治療應用

專注於 CRISPR-Cas 系統

細分市場洞察

產品與服務見解

最終用途見解

區域洞察

目錄

第 1 章：產品概述

第 2 章：研究方法

第 3 章：客戶之聲

第 4 章：執行摘要

第 5 章：全球 gRNA 市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按類型（研究用途、GMP 級）
    • 按產品和服務（產品（gRNA 最終產品、gRNA 合成產品、gRNA 合成試劑盒、質粒、其他））、客製化 gRNA 合成服務）
    • 按應用（基因組工程、疾病模型研究、功能基因體學、表觀遺傳學等）
    • 按最終用途（製藥和生物技術公司、學術研究機構、CMO 和 CRO）
    • 按地區
    • 按公司分類 (2023)
  • 市場地圖
    • 按類型
    • 按產品和服務
    • 按申請
    • 按最終用途
    • 按地區

第 6 章：亞太 gRNA 市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按類型
    • 按產品和服務
    • 按申請
    • 按最終用途
    • 按國家/地區
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 澳洲
    • 日本
    • 韓國

第 7 章：歐洲 gRNA 市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按類型
    • 按產品和服務
    • 按申請
    • 按最終用途
    • 按國家/地區
  • 歐洲：國家分析
    • 法國
    • 德國
    • 西班牙
    • 義大利
    • 英國

第 8 章：北美 gRNA 市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按類型
    • 按產品和服務
    • 按申請
    • 按最終用途
    • 按國家/地區
  • 北美：國家分析
    • 美國
    • 墨西哥
    • 加拿大

第 9 章：南美洲 gRNA 市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按類型
    • 按產品和服務
    • 按申請
    • 按最終用途
    • 按國家/地區
  • 南美洲：國家分析
    • 巴西
    • 阿根廷
    • 哥倫比亞

第 10 章：中東和非洲 gRNA 市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按類型
    • 按產品和服務
    • 按申請
    • 按最終用途
    • 按國家/地區
  • MEA：國家分析
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 埃及

第 11 章：市場動態

  • 促進要素
  • 挑戰

第 12 章：市場趨勢與發展

  • 最近的發展
  • 產品發布（如有）
  • 併購（如有）

第 13 章：全球 gRNA 市場：SWOT 分析

第 14 章：波特的五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的力量
  • 客戶的力量
  • 替代產品的威脅

第15章：競爭格局

  • Thermo Fisher Scientific, Inc.
  • Agilent Technologies, Inc.
  • System Biosciences, LLC
  • Jena Bioscience GmbH
  • Merck KGaA
  • Azenta Us, Inc.
  • Takara Bio, Inc.
  • Synbio Technologies
  • Revvity, Inc.
  • Synthego Corporation

第 16 章：策略建議

第17章調查會社について,免責事項

簡介目錄
Product Code: 23789

Global gRNA Market was valued at USD 498.23 million in 2023 and is anticipated to grow with a CAGR of 18.54% through 2029. The gRNA (guide RNA) market has emerged as a dynamic and promising sector within the field of genetic engineering and genome editing. As advancements in biotechnology and molecular biology continue to accelerate, the demand for precise and efficient genome editing tools has risen significantly, driving the expansion of the gRNA market. gRNA serves as a critical component in CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) technology, which enables targeted modification of genes. This revolutionary technology has applications across various sectors, including agriculture, healthcare, and research. In agriculture, the use of gRNA in CRISPR-based genome editing has the potential to revolutionize crop improvement by enhancing traits such as yield, resistance to diseases, and nutritional content. The healthcare industry is also witnessing a surge in the adoption of gRNA technology for therapeutic purposes, including the development of novel treatments for genetic disorders and cancers. The versatility of gRNA allows scientists and researchers to precisely target and modify specific genes, opening up possibilities for personalized medicine. The gRNA market is characterized by ongoing research and development activities aimed at refining and expanding the capabilities of CRISPR technology. The race to develop more efficient and precise genome editing tools has spurred collaborations between biotechnology companies, academic institutions, and research organizations. As a result, the gRNA market is expected to witness continuous growth in the coming years. However, ethical and regulatory challenges associated with genome editing technologies, including concerns about off-target effects and unintended consequences, pose potential obstacles to the market's expansion. Striking a balance between technological advancement and ethical considerations will be crucial for the sustained growth of the gRNA market. Despite challenges, the potential applications and transformative impact of gRNA technology make it a focal point in the rapidly evolving landscape of genetic engineering.

Market Overview
Forecast Period2025-2029
Market Size 2023USD 498.23 Million
Market Size 2029USD 1370.40 Million
CAGR 2024-202918. 54%
Fastest Growing SegmentPharmaceutical & Biotechnology Companies
Largest MarketNorth America

Key Market Drivers

Advancements in Genetic Engineering

Advancements in genetic engineering have been instrumental in shaping the landscape of the global gRNA (guide RNA) market. The relentless pursuit of precision and efficiency in genome editing technologies, particularly CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats), has led to groundbreaking developments with far-reaching implications. Scientists and researchers have made significant strides in refining the mechanisms of gRNA, allowing for more accurate targeting and modification of specific genes. These advancements have not only expanded the scope of genetic engineering applications but have also fueled the commercialization of gRNA technologies across diverse sectors. One notable breakthrough is the continuous improvement in CRISPR-Cas systems, with an emphasis on reducing off-target effects and enhancing on-target precision. This progress has bolstered confidence in the safety and efficacy of genome editing tools, driving increased adoption across industries. The development of high-throughput screening techniques and innovative delivery methods for gRNA has further streamlined the gene-editing process, making it more accessible and applicable in various research and commercial settings. The global gRNA market has been positively influenced by these advancements, attracting substantial investments and partnerships between biotechnology firms and research institutions. The synergistic collaboration between technology developers and end-users has facilitated the integration of cutting-edge genetic engineering tools, fostering a robust market environment. As genetic engineering continues to evolve, the gRNA market stands at the forefront, poised to leverage ongoing advancements for applications ranging from agriculture to personalized medicine.

Increased Research and Development Activities

The global gRNA (guide RNA) market is experiencing significant expansion, propelled by a surge in research and development activities aimed at advancing genome editing technologies. Research initiatives focused on enhancing the precision, efficiency, and safety of gRNA, particularly in the context of CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats), have become a cornerstone of innovation in the field. Scientists and biotechnologists are actively engaged in understanding the intricacies of gRNA design, delivery methods, and the overall CRISPR system, leading to breakthroughs that address existing challenges and broaden the range of applications. Increased R&D efforts have resulted in the development of novel gRNA variants, with improved specificity and reduced off-target effects, fostering greater confidence in the reliability of genome editing tools. Continuous exploration of alternative CRISPR systems and bioinformatics tools has expanded the toolkit available to researchers, enabling them to navigate the complexities of gene editing with greater precision. The efforts to optimize the delivery of gRNA into target cells have contributed to the development of more efficient and scalable methods, making genome editing more accessible across various industries. The collaborative nature of these research endeavors, involving academia, industry, and research institutions, has accelerated the pace of discovery in the gRNA field. This heightened research activity not only fuels the evolution of genetic engineering technologies but also attracts substantial investments, driving the commercialization of advanced gRNA applications. The global gRNA market is thus intricately linked to the dynamic landscape of research and development, with ongoing efforts shaping its trajectory and ensuring its continued growth and relevance in diverse sectors.

Rising Demand for Personalized Medicine

The global gRNA (guide RNA) market is witnessing a compelling surge in demand, driven in no small part by the rising prominence of personalized medicine. As the understanding of the human genome advances, there is an increasing recognition of the potential of gRNA technology, particularly within the CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) framework, to revolutionize healthcare. Personalized medicine aims to tailor medical treatments to individual genetic profiles, and gRNA plays a pivotal role in this paradigm shift. The ability of gRNA to precisely target and modify specific genes opens avenues for developing customized therapies for a spectrum of genetic disorders, ranging from rare diseases to more prevalent conditions. This demand is underscored by the quest to find targeted and effective treatments with minimal side effects, aligning with the ethos of precision medicine. The pharmaceutical industry is increasingly investing in research and development initiatives centered on gRNA applications, striving to unlock the full therapeutic potential of genome editing. The advent of CRISPR-based gene therapies for various genetic disorders has heightened interest in the gRNA market, creating a symbiotic relationship between the demand for personalized medicine and the technological capabilities of gRNA. The gRNA market, as an integral component of the personalized medicine landscape, is poised for substantial growth. The convergence of cutting-edge genetic engineering technologies with the paradigm shift towards individualized healthcare is reshaping the global healthcare landscape and positioning gRNA as a cornerstone in the quest for more effective and tailored medical interventions.

Key Market Challenges

Off-Target Effects

Off-target effects represent a significant challenge in the global gRNA (guide RNA) market, posing concerns about the precision and safety of genome editing technologies. Off-target effects occur when the CRISPR system, guided by gRNA, inadvertently modifies unintended genomic locations, leading to potentially unpredictable consequences. This phenomenon is a critical consideration in therapeutic applications, as unintended alterations to the genome could result in adverse effects or unintended mutations. Researchers are actively engaged in developing strategies to minimize off-target effects, employing advanced bioinformatics tools, improved gRNA design algorithms, and enhanced CRISPR enzyme engineering. Despite ongoing efforts, achieving complete elimination of off-target effects remains a complex task. The unique characteristics of individual genomes, variations in target sequences, and the complexity of genomic interactions contribute to the challenge. As the demand for precision genome editing increases, the gRNA market is driven by innovations aimed at refining and optimizing CRISPR technologies to mitigate the risks associated with off-target effects. Addressing off-target effects is not only crucial for therapeutic applications but also essential in other sectors such as agriculture and research. Striking a balance between efficiency and precision is paramount to harness the full potential of gRNA technology without compromising safety. The market's response to this challenge involves continuous research, technological advancements, and a collaborative effort among scientists, industry stakeholders, and regulatory bodies to establish guidelines that ensure responsible and reliable use of gRNA-based genome editing tools. The resolution of off-target effects is pivotal in fostering confidence in the gRNA market and unlocking its diverse applications across various fields.

Delivery Methods

Efficient delivery methods constitute a critical aspect of the global gRNA (guide RNA) market, playing a pivotal role in determining the success of genome editing applications, particularly within the CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) framework. The challenge lies in delivering gRNA into target cells with precision, avoiding off-target effects and ensuring the effective incorporation of genetic modifications. Various delivery methods are under constant exploration and development to optimize the efficiency, safety, and scalability of gRNA technology. Viral vectors, such as lentiviruses and adeno-associated viruses (AAVs), have been widely employed for delivering gRNA into cells due to their ability to efficiently integrate genetic material. However, concerns about immunogenicity, limited cargo capacity, and potential side effects necessitate ongoing research into alternative delivery platforms. Non-viral methods, including lipid nanoparticles, electroporation, and physical methods like microinjection, are being investigated for their potential to provide safer and more cost-effective delivery solutions. The choice of delivery method is influenced by the specific application and target cells, emphasizing the need for versatility in the gRNA market. Innovations in nanotechnology and biomaterials contribute to the development of delivery systems that enhance cell specificity, reduce toxicity, and improve the overall efficacy of gRNA delivery. Overcoming delivery challenges is crucial for expanding the reach of gRNA technologies, ensuring their applicability in diverse industries such as therapeutics, agriculture, and research. As the global gRNA market continues to evolve, advancements in delivery methods will play a pivotal role in shaping the accessibility and effectiveness of genome editing tools across various sectors.

Key Market Trends

Therapeutic Applications

The global gRNA (guide RNA) market is witnessing a notable trend with the increasing prominence of therapeutic applications, marking a transformative era in medicine. The rise of gRNA technology, particularly within the CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) framework, has opened unprecedented opportunities for the development of targeted and personalized therapies. Researchers and pharmaceutical companies are actively exploring the therapeutic potential of gRNA in treating genetic disorders, rare diseases, and certain types of cancers. Clinical trials and research endeavors are underway to harness the precision of gRNA for gene editing in somatic cells, offering the prospect of novel and more effective treatment modalities. The ability of gRNA to precisely target and modify specific genes holds promise for addressing the root causes of genetic diseases at the molecular level. This trend aligns with the broader movement towards precision medicine, where treatments are tailored to individual genetic profiles. As the therapeutic landscape continues to evolve, the gRNA market is positioned as a key player in ushering in a new era of customized medical interventions. Challenges such as off-target effects and ethical considerations remain, but the growing interest and investment in therapeutic applications underscore the potential of gRNA to revolutionize healthcare and contribute significantly to the advancement of precision medicine. The upward trajectory of therapeutic applications is expected to be a driving force in the continued growth and diversification of the global gRNA market.

Focus on CRISPR-Cas Systems

The global gRNA (guide RNA) market is experiencing a distinct trend marked by a heightened focus on CRISPR-Cas systems. As the cornerstone of precise genome editing, CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) technology relies on guide RNA to direct Cas proteins to specific genomic locations, enabling targeted modifications. The continuous refinement and optimization of CRISPR-Cas systems have become a focal point of research and development within the gRNA market. Scientists and biotechnologists are actively engaged in exploring novel Cas proteins, engineering existing ones for enhanced specificity, and developing alternative CRISPR systems beyond the well-known Cas9. This trend is driven by the quest for greater precision and reduced off-target effects in genome editing applications. The versatility of CRISPR-Cas systems allows researchers to tailor their approach to different genetic contexts and overcome challenges associated with specific gene-editing scenarios. The rise in interest extends beyond academic research, with biotechnology companies investing significantly in the development of CRISPR-based tools for applications in therapeutics, agriculture, and various research fields. As CRISPR-Cas systems become more sophisticated and adaptable, the gRNA market is poised to benefit from the expanding toolkit of genome editing technologies. The focus on CRISPR-Cas systems aligns with the market's pursuit of refining and advancing gRNA technology, making it an integral component in the continuous evolution of genetic engineering and its diverse applications across industries.

Segmental Insights

Product & Services Insights

Based on Product & Services, product segment dominated the Global gRNA Market in 2023. This is ascribed due to the pivotal role of gRNA as a key component in CRISPR-based gene editing systems. Researchers and biotechnology companies widely utilize gRNA products to design and customize CRISPR experiments for targeted gene modifications. The demand for high-quality, reliable gRNA products for precise and efficient gene editing drives the dominance of this segment. As CRISPR technology becomes increasingly essential in various fields, including medicine and agriculture, the popularity and reliance on gRNA products for genetic manipulation contribute significantly to their dominance in the global market.

End Use Insights

Based on end use, pharmaceutical and biotechnology companies segment dominated the Global gRNA Market in 2023. This is ascribed due to its pivotal role in driving research, development, and commercialization of gene-editing technologies. These companies possess the expertise, infrastructure, and financial resources required for innovative gRNA (guide RNA) applications like CRISPR-Cas9. With a focus on therapeutic advancements, these firms lead in translating gene-editing discoveries into viable treatments for genetic disorders, cancers, and other diseases. The dominance of this segment underscores the critical involvement of pharmaceutical and biotechnology companies in advancing gRNA technologies from laboratories to clinical applications, shaping the market landscape with cutting-edge genetic therapies.

Regional Insights

North America dominate the global gRNA market in 2023. The region's dominance is notably influenced by the significant presence of key industry players in the region. This local concentration of major players contributes to the overall growth of the gRNA industry in North America. The region experiences a surge in research and development investments by these key players, aimed at fostering the creation of innovative and advanced gRNA products. The collaborative efforts of industry leaders and increased R&D spending collectively propel North America to the forefront of the global gRNA market.

Key Market Players

Thermo Fisher Scientific Inc.

Agilent Technologies, Inc.

System Biosciences, LLC

Jena Bioscience GmbH

Merck KGaA

Azenta US, Inc.

Takara Bio, Inc.

Synbio Technologies

Revvity, Inc.

Synthego Corporation

Report Scope:

In this report, the Global gRNA Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

gRNA Market, By Type:

    Research-Use GMP-grade

gRNA Market, By Product & Services:

    Products

gRNA Final Products

gRNA Synthesis Products

gRNA Synthesis Kits

Plasmids

Others

    Custom gRNA Synthesis Services

gRNA Market, By Application:

    Genome Engineering Disease Model Studies Functional Genomics Epigenetics Others

gRNA Market, By End Use:

    Pharmaceutical & Biotechnology Companies Academic Research Institutes CMOs & CROs

gRNA Market, By Region:

    North America

United States

Canada

Mexico

    Europe

France

United Kingdom

Italy

Germany

Spain

    Asia-Pacific

China

India

Japan

Australia

South Korea

    South America

Brazil

Argentina

Colombia

    Middle East & Africa

South Africa

Saudi Arabia

UAE

Egypt

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global gRNA Market.

Available Customizations:

Global gRNA Market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Voice of Customer

4. Executive Summary

  • 4.1. Overview of the Market
  • 4.2. Overview of Key Market Segmentations
  • 4.3. Overview of Key Market Players
  • 4.4. Overview of Key Regions/Countries
  • 4.5. Overview of Market Drivers, Challenges, Trends

5. Global gRNA Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Type (Research-Use, GMP-grade)
    • 5.2.2. By Product & Services (Products (gRNA Final Products, gRNA Synthesis Products, gRNA Synthesis Kits, Plasmids, Others)), Custom gRNA Synthesis Services)
    • 5.2.3. By Application (Genome Engineering, Disease Model Studies, Functional Genomics, Epigenetics, Others)
    • 5.2.4. By End-Use (Pharmaceutical & Biotechnology Companies, Academic Research Institutes, CMOs & CROs)
    • 5.2.5. By Region
    • 5.2.6. By Company (2023)
  • 5.3. Market Map
    • 5.3.1. By Type
    • 5.3.2. By Product & Services
    • 5.3.3. By Application
    • 5.3.4. By End-Use
    • 5.3.5. By Region

6. Asia Pacific gRNA Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Type
    • 6.2.2. By Product & Services
    • 6.2.3. By Application
    • 6.2.4. By End-Use
    • 6.2.5. By Country
  • 6.3. Asia Pacific: Country Analysis
    • 6.3.1. China gRNA Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Type
        • 6.3.1.2.2. By Product & Services
        • 6.3.1.2.3. By Application
        • 6.3.1.2.4. By End-Use
    • 6.3.2. India gRNA Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Type
        • 6.3.2.2.2. By Product & Services
        • 6.3.2.2.3. By Application
        • 6.3.2.2.4. By End-Use
    • 6.3.3. Australia gRNA Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Type
        • 6.3.3.2.2. By Product & Services
        • 6.3.3.2.3. By Application
        • 6.3.3.2.4. By End-Use
    • 6.3.4. Japan gRNA Market Outlook
      • 6.3.4.1. Market Size & Forecast
        • 6.3.4.1.1. By Value
      • 6.3.4.2. Market Share & Forecast
        • 6.3.4.2.1. By Type
        • 6.3.4.2.2. By Product & Services
        • 6.3.4.2.3. By Application
        • 6.3.4.2.4. By End-Use
    • 6.3.5. South Korea gRNA Market Outlook
      • 6.3.5.1. Market Size & Forecast
        • 6.3.5.1.1. By Value
      • 6.3.5.2. Market Share & Forecast
        • 6.3.5.2.1. By Type
        • 6.3.5.2.2. By Product & Services
        • 6.3.5.2.3. By Application
        • 6.3.5.2.4. By End-Use

7. Europe gRNA Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Type
    • 7.2.2. By Product & Services
    • 7.2.3. By Application
    • 7.2.4. By End-Use
    • 7.2.5. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. France gRNA Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Type
        • 7.3.1.2.2. By Product & Services
        • 7.3.1.2.3. By Application
        • 7.3.1.2.4. By End-Use
    • 7.3.2. Germany gRNA Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Type
        • 7.3.2.2.2. By Product & Services
        • 7.3.2.2.3. By Application
        • 7.3.2.2.4. By End-Use
    • 7.3.3. Spain gRNA Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Type
        • 7.3.3.2.2. By Product & Services
        • 7.3.3.2.3. By Application
        • 7.3.3.2.4. By End-Use
    • 7.3.4. Italy gRNA Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Type
        • 7.3.4.2.2. By Product & Services
        • 7.3.4.2.3. By Application
        • 7.3.4.2.4. By End-Use
    • 7.3.5. United Kingdom gRNA Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Type
        • 7.3.5.2.2. By Product & Services
        • 7.3.5.2.3. By Application
        • 7.3.5.2.4. By End-Use

8. North America gRNA Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Type
    • 8.2.2. By Product & Services
    • 8.2.3. By Application
    • 8.2.4. By End-Use
    • 8.2.5. By Country
  • 8.3. North America: Country Analysis
    • 8.3.1. United States gRNA Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Type
        • 8.3.1.2.2. By Product & Services
        • 8.3.1.2.3. By Application
        • 8.3.1.2.4. By End-Use
    • 8.3.2. Mexico gRNA Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Type
        • 8.3.2.2.2. By Product & Services
        • 8.3.2.2.3. By Application
        • 8.3.2.2.4. By End-Use
    • 8.3.3. Canada gRNA Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Type
        • 8.3.3.2.2. By Product & Services
        • 8.3.3.2.3. By Application
        • 8.3.3.2.4. By End-Use

9. South America gRNA Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Type
    • 9.2.2. By Product & Services
    • 9.2.3. By Application
    • 9.2.4. By End-Use
    • 9.2.5. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil gRNA Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Type
        • 9.3.1.2.2. By Product & Services
        • 9.3.1.2.3. By Application
        • 9.3.1.2.4. By End-Use
    • 9.3.2. Argentina gRNA Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Type
        • 9.3.2.2.2. By Product & Services
        • 9.3.2.2.3. By Application
        • 9.3.2.2.4. By End-Use
    • 9.3.3. Colombia gRNA Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Type
        • 9.3.3.2.2. By Product & Services
        • 9.3.3.2.3. By Application
        • 9.3.3.2.4. By End-Use

10. Middle East and Africa gRNA Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Type
    • 10.2.2. By Product & Services
    • 10.2.3. By Application
    • 10.2.4. By End-Use
    • 10.2.5. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa gRNA Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Type
        • 10.3.1.2.2. By Product & Services
        • 10.3.1.2.3. By Application
        • 10.3.1.2.4. By End-Use
    • 10.3.2. Saudi Arabia gRNA Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Type
        • 10.3.2.2.2. By Product & Services
        • 10.3.2.2.3. By Application
        • 10.3.2.2.4. By End-Use
    • 10.3.3. UAE gRNA Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Type
        • 10.3.3.2.2. By Product & Services
        • 10.3.3.2.3. By Application
        • 10.3.3.2.4. By End-Use
    • 10.3.4. Egypt gRNA Market Outlook
      • 10.3.4.1. Market Size & Forecast
        • 10.3.4.1.1. By Value
      • 10.3.4.2. Market Share & Forecast
        • 10.3.4.2.1. By Type
        • 10.3.4.2.2. By Product & Services
        • 10.3.4.2.3. By Application
        • 10.3.4.2.4. By End-Use

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Recent Developments
  • 12.2. Product Launches (If Any)
  • 12.3. Mergers & Acquisitions (If Any)

13. Global gRNA Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Thermo Fisher Scientific, Inc.
    • 15.1.1. Business Overview
    • 15.1.2. Company Snapshot
    • 15.1.3. Products & Services
    • 15.1.4. Financials (In case of listed)
    • 15.1.5. Recent Developments
    • 15.1.6. SWOT Analysis
  • 15.2. Agilent Technologies, Inc.
  • 15.3. System Biosciences, LLC
  • 15.4. Jena Bioscience GmbH
  • 15.5. Merck KGaA
  • 15.6. Azenta Us, Inc.
  • 15.7. Takara Bio, Inc.
  • 15.8. Synbio Technologies
  • 15.9. Revvity, Inc.
  • 15.10.Synthego Corporation

16. Strategic Recommendations

17. About Us & Disclaimer